Status | Study |
Completed |
Study Name: Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® Condition: Essential Thrombocythaemia Date: 2011-05-10 Interventions: Drug: Anagrelide hydrochloride 0.5 mg hard capsules, dosing decisions will be made by the treating physi |
Active, not recruiting |
Study Name: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Condition: High Risk Polycythemia Vera High Risk Essential Thrombocythemia Date: 2010-12-07 Interventions: Drug: PEGASYS The subject will |
Completed |
Study Name: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Condition: High Risk Polycythemia Vera High Risk Essential Thrombocythemia Date: 2010-12-06 Interventions: Drug: PEGASYS Patient will sta |
Completed |
Study Name: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Condition: Essential Thrombocythemia Polycythemia Vera Date: 2010-11-11 Interventions: Drug: Imetelstat |
Completed |
Study Name: Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Condition: Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Date: 2010-11-05 Interventions: Drug: Momelotinib Patients will continue receiving the same doses as assigned during the CCL09101 protoc |
Completed |
Study Name: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Condition: Essential Thrombocythaemia Date: 2010-10-28 Interventions: Drug: Anagrelide retard |
Completed |
Study Name: Pediatric Disease Registry in Essential Thrombocythaemia (ET) Condition: Essential Thrombocythemia (ET) Date: 2010-09-08 |
Completed |
Study Name: French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia Condition: Essential Thrombocythemia Date: 2010-08-26 |
Completed |
Study Name: Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Condition: Essential Thrombocythaemia Date: 2010-02-08 Interventions: Drug: Anagrelide Drug: Hydroxyurea |
Completed |
Study Name: Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Condition: Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Date: 2009-07-07 Interventions: Drug: CYT387 For the Part 1 dose-escalation portion of the |